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A B S T R A C T
This paper reports the development and performance of an electrochemical immunosensor using magnetic multi-
walled carbon nanotubes (m-MWCNTs) as nanocarrier tags for the determination of human fetuin A (HFA), a rel-
evant biomarker of obesity, insulin resistance, and type-2 diabetes as well as for pancreatic and liver cancers and
inflammatory processes. Screen-printed carbon electrodes were grafted with p-aminobezoic acid and streptavidin
was covalently immobilized on the electrode surface. A biotinylated capture antibody was immobilized through
streptavidin-biotin interaction and a sandwich assay configuration was implemented using m-MWCNTs conju-
gated with HRP and anti-HFA antibodies as the detection label. The determination of HFA was accomplished
by measuring the current produced by the electrochemical reduction of benzoquinone at −200mV upon addi-
tion of H⁠2O⁠2 as HRP substrate. The prepared m-MWCNTs were characterized by SEM, TEM, XRD and EDS. All
the steps involved in the immunosensor preparation were monitored by electrochemical impedance spectroscopy
and cyclic voltammetry. A linear calibration plot for HFA was found between 20 and 2000pg/mL with a LOD
value of 16pg/mL. This performance is notably better than that reported for an ELISA kit and a chronoimpedi-
metric immunosensor. The favorable contribution of m-MWCNTs in comparison with MWCNTs without incorpo-
rated magnetic particles to this excellent analytical performance is also highlighted. The immunosensor selectiv-
ity against other proteins and potentially interfering compounds was excellent. In addition, the usefulness of the
immunosensor was demonstrated by the analysis of HFA in saliva with minimal sample treatment.
1. Introduction
Human Fetuin A (HFA), also known as α2-Heremans-Schmid glyco-
protein (AHSG), is encoded by the AHSG gene on chromosome 3. Plas-
matic HFA is a 59kDa disulfide bond-linked two chain polypeptide con-
sisting of two N-terminal cystatin domains and a smaller C-terminal do-
main (Dziegielewska et al., 1990). HFA is considered as a candidate
biomarker of obesity, insulin resistance, and type-2 diabetes. High HFA
serum concentrations have been observed in individuals with fatty or
swollen liver (Yilmaz et al., 2010) related with increased risk of type-2
diabetes (Dabrowska et al., 2015). The relevance of HFA as a new po-
tential biomarker for pancreatic and liver cancers and in metastasis of
tumor cells (Sakwe et al., 2010) (Yi et al., 2009) as well as to differenti-
ate prostate cancer and benign prostatic hyperplasia (Silva et al., 2016)
has been also claimed.
In addition, the synthesis of HFA is down-regulated during injury
and inflammation (Choi, 2016) and plays an important role in blood
vessel calcification (Schinke et al., 1996). As HFA acts as a potent in-
hibitor of calcium-phosphate precipitation and the calcification process,
its levels are also related with dental calculus which is the first response
in the inflammation of tooth supportive tissues (Doğan et al., 2016).
Therefore, the relationship between HFA and the periodontal disease
makes the determination of HFA in saliva relevant.
Due to the clinical importance of HFA, assays using different biore-
agents for HFA detection have emerged. Table S1 in the Supplemen-
tary material summarizes the characteristics of commercially available
ELISA kits involving sandwich-type configurations, peroxidase-labeled
immunoreagents and colorimetric detection through the TMB/H⁠2O⁠2 sys-
tem. For instance, the Quantikine Human Fetuin A Immunoassay (https:
//www.rndsystems.com/products/human-fetuin-a-quantikine-elisa-kit_
dfta00) is a 4.5-h solid-phase colorimetric ELISA that provides a cal-
ibration plot in the 7.8–500ng/mL range and a minimum de
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tectable dose (MDD), defined as the concentration corresponding to the
mean absorbance of zero standard replicates (n=20) +2s, of 0.62ng/
mL.
In the case of electrochemical biosensors, the strong interaction of
HFA glycoprotein with specific lectins has been explored (Table S1).
Specifically, Bertok et al. (2013a, 2013b) developed an impedimet-
ric biosensor involving the Sambucus nigra lectin and a mixed SAM of
11-mercaptoundecanoic acid and 6-mercaptohexanol. Biorecognition of
fetuin was accomplished through carboxyl group activation and lectin
adhesion. Electrochemical impedance spectroscopy (EIS) was used as
transduction technique. The same authors developed a more sensitive
biosensor where a linker layer of amino-terminated alkanethiol was as-
sembled on a gold electrode for further incorporation of gold nanopar-
ticles The limit of detection achieved was 0.5±0.1aM (Bertok et al.,
2013a, 2013b).
Nagaraj et al. (2010) developed another lectin-based biosensor for
the label-free detection of HFA. They used a silicon chip with a row
of gold electrodes and relied on the impedance variations upon HFA
binding to lectins. The limit of detection was 1pg/mL. Moreover, a la-
bel-free electrochemical biosensor using Cratyliamollis lectin (Cramoll
1,4), assembled carboxylated carbon nanotubes and poly-L-lysine film
was also proposed using square-wave voltammetry. A limit of detection
of 0.017μg/mL was achieved (Silva et al., 2016) (Table S1).
It is well known that the advantageous analytical capabilities of elec-
trochemical immunosensors become more evident when using nanoma-
terials which can increase the loading of electrochemically detectable
species as well as catalyze the electrochemical reaction enhancing the
electrochemical signal (Ding et al., 2013). Carbon nanomaterials can be
utilized in different amplification routes in electrochemical biosensing
which mainly imply their use as electrode materials, redox mediators
or carriers for signaling elements (Yáñez-Sedeño et al., 2017). Very re-
cently, a fullerene-PAMAM(G5) composite was used for the preparation
of a chronoimpedimetric immunosensor for HFA showing a 5–400ng/
mL linear range with a LOD of 1.44ng/mL (Uygun et al., 2018).
Apart from this article, to our knowledge, there are no other con-
figurations reported for electrochemical immunosensors for HFA. Here,
we describe the development and performance of an electrochemical
immunosensor using magnetic multiwalled carbon nanotubes (m-MW-
CNTs) as nanocarrier tags for the determination of HFA in the
20–1000pg/mL with a LOD of 16pg/mL. Screen-printed carbon elec-
trodes were modified by grafting with p-aminobezoic acid and, upon ac-
tivation of the surface-confined carboxylic groups, streptavidin was co-
valently immobilized and, after conjugation with biotin-anti-HFA cap-
ture antibody, a sandwich scheme was prepared using m-MWC-
NTs(-HRP)-anti-HFA conjugates as the detection label. The excellent
biosensor performance allowed the determination of HFA in saliva at
clinical levels.
2. Experimental
2.1. Reagents and solutions
The antibodies used and the HFA protein were those included in
the DuoSet®ELISA Development System from R&D Systems (DY1184).
A goat biotinylated anti-HFA antibody was used as the capture anti-
body. Biotin-anti-HFA 36µg/mL solutions in phosphate buffer of pH 7.4
were also used. Detection antibody was a mouse anti-HFA dissolved in
the same buffer solution. Aqueous streptavidin (Strept, Sigma) solutions
were firstly prepared and diluted with 25mM 2–(N–morpholine)ethane-
sulfonic (MES) (Gerbu) of pH 5.0. Lithium perchlorate (Sigma),
p-aminobenzoic acid (pABA, Acros), and absolute ethanol (VWR Chem-
icals) were used for the grafting protocol. Covalent immobilization
of capture antibody was carried out with 1–ethyl–3–(3–di
methylaminopropyl) carbodiimide (EDC) and sodium N–hydroxysulfos-
uccinimide (NHSS) (Acros). D-biotin (Gerbu) was used as the blocking
agent. Solutions were prepared in phosphate buffer of pH 7.4.
Ascorbic acid (AA, Fluka), uric acid (UA, Sigma), bovine serum al-
bumin (BSA, Gerbu), cortisol (CL), creatinine (CR), estradiol (E2) and
human immunoglobulin G (IgG), all from Sigma, interleukin-1 beta
(IL–1β), transforming growth factor beta 1 (TGF-β1), and tumor necro-
sis factor alpha (TNF-α), all from R&D Systems, interleukin-6 (IL–6) and
interleukin-8 (IL–8) from Abcam, were checked as potential interfer-
ents. Hydrogen peroxide (Aldrich, 30% (w/w)) and hydroquinone (HQ,
Sigma) were also used.
Other buffer solutions used were: 0.01M phosphate buffer saline
(PBS) of pH 7.4 prepared by dissolving Na⁠2HPO⁠4 (Scharlau) and KH⁠2PO⁠4
(Merck) in 137mM NaCl (Labkem) and 2.7mM KCl (Probus) aque-
ous solution. 0.1M and 0.01M PBS of pH 7.0 prepared by dissolving
Na⁠2HPO⁠4 and NaH⁠2PO⁠4 (Labkem) in 150mM NaCl aqueous solution;
0.1M PBST of pH 7.0 prepared by adding 5μL of Tween® 20–10mL of
0.1M PBS of pH 7.0, and 0.05M phosphate buffer (PB) of pH 6.0 pre-
pared by dissolving 2.180g of K⁠2HPO⁠4 in distilled water and adjusting
the pH value.
All reagents used were of analytical grade. Deionized water
(18.2MΩcm at 25°C) was obtained from a Millipore Milli–Q purifica-
tion system.
2.2. Apparatus and electrodes
Amperometric measurements were done with an INBEA Biosensores
potentiostat equipped with the Ib-Graph software. Impedimetric and
voltammetric measurements were performed with a μAutolab type III
potentiostat controlled by FRA2 and GPES 4.7 (EcoChemie) softwares,
respectively. A Crison Basic 20+pHmeter, an ultrasonic bath Elmasonic
S–60 (Elma), a Vortex (Velp Scientifica) stirrer, and a Dynal MPC–S
120.20 (Dynal BiotechASA) magnetic separator, were also used. Char-
acterization by SEM, EDX, TEM and XRD were performed using a FE-
SEM (Field Emission Scanning Electron Microscope): JEOL JSM 7600F,
a TEM: JEOL JEM 1400, and a difractometer PAMalytical model X´Pert
MPD.
Screen printed carbon electrodes (SPCEs, 110 DRP, ϕ4mm) were
from DropSens (Oviedo, Spain). These electrodes were provided with a
carbon counter electrode and a silver pseudo-reference electrode.
2.3. Procedures
2.3.1. Preparation of the modified SPCEs
The screen-printed carbon electrodes were modified by immersion
in an ethanolic p-ABA solution containing LiClO⁠4 and making three suc-
cessive cyclic voltammograms between 0.0 and 0.6V at 30mV/s. Then,
the modified electrodes were washed with deionized water and let dry
at air. The grafted surface carboxylic groups were activated by dropping
10μL of a 100mM each EDC/NHSS solution prepared in 25mM MES
buffer of pH 5.0, and allowing incubation for 30min. Once the elec-
trodes were washed and dried again, modification with streptavidin was
performed by casting 5μL of a 600μg/mL Strept solution prepared in
the same buffer solution and incubating for 60min.
2.3.2. Preparation of magnetic MWCNTs
25mg of MWCNTs were dispersed in 85mL of Milli–Q water by ul-
trasonic stirring for one hour. Then, 16mL of concentrated nitric acid
were added and refluxed for 24h. The resulting dispersion was cen-
trifuged at 4000rpm for 10min at room temperature. The carboxy-
lated MWCNTs were washed with Milli–Q water up to washing water
reached pH 7.0 and let dry under nitrogen stream. Magnetization of
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the resulting HOOC-MWCNTs was performed by suspending 19.4mg in
10mL of water, adding 13.1mg of FeCl⁠3·6H⁠2O and 5.9mg of FeCl⁠2·4H⁠2O
and adjusting the pH value at 10–11 with a 25% aqueous ammonia so-
lution by applying ultrasonic stirring for 30min under nitrogen atmos-
phere. The resulting dispersion was maintained at 80°C under magnetic
stirring and nitrogen atmosphere for 60min. Finally, once cold at room
temperature, the resulting m-MWCNTs were washed with water up to
neutral pH and dried at 37°C.
2.3.3. Preparation of m-MWCNTs(-HRP)-anti-HFA conjugates
A dispersion was prepared with 1.5mg of m-MWCNTs in 2mL of
100mM PBS of pH 7.0 with ultrasonic stirring for 30min. Next, 1mL
of a solution composed of 400mM EDC and 100mM NHSS in the same
buffer was added and incubated in the dark with magnetic stirring for
6h. The resulting suspension was centrifuged at 14,000rpm and room
temperature during 5min and, thereafter, 1mL of a solution contain-
ing 5µg/mL of detection antibody (anti–HFA) and 1mg/mL of HRP in
100mM PBS of pH 7.0 was added. After an incubation period of 24h
under magnetic stirring, the conjugates were washed three times with
10mM PBS of pH 7.0, and the residue was re-dispersed in 1mL of
100mM PBST of pH 7.0.
2.3.4. Preparation of anti-HFA-Biotin-Strept-Phe-SPCE immunosensor
Grafted SPCEs (Procedure 2.3.1) were treated with 5μL of a 100mM
each EDC/NHSS solution in 25mM MES buffer of pH 5.0 and incubated
for 30min. Then, the modified electrode was washed with water and
let dry. Immobilization of Strept was performed by dropping 5μL of a
600µg/mL solution in the same buffer and incubation for 60min. Once
the Strept-Phe-SPCEs were washed with water and dried, the biotiny-
lated capture antibody (Biotin–anti–HFA) was immobilized by deposit-
ing 5μL of a 7μg/mL solution in 0.01M PBS of pH 7.4 and incubated for
60min. A blocking step was implemented by adding 5μL of a 1.5mg/
mL Biotin solution and incubation for 30min.
2.3.5. Determination of HFA
After a washing and drying step, 5μL of antigen solution (or the
sample) were added and incubated for 60min onto the resulting
anti-HFA-Biotin-Strept-Phe-SPCE immunosensor. Thereafter, 5μL of the
m-MWCNTs(–HRP)–anti–HFA conjugate were added and, after 60min,
the bioelectrodes were washed with water and then stored until use
by addition of a drop of 50mM phosphate buffer solution of pH 6.0.
The determination of HFA was accomplished by dropping 45μL of
a 1mM HQ solution prepared in 0.5M phosphate buffer solution of
pH 6.0 onto the surface of the horizontally postioned m-MWC-
NTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE im-
munosensor and by applying a potential of −200mV. Once the back-
ground current was stabilized (100s approximately), 5μL of a 50mM
H⁠2O⁠2 solution prepared in the same buffer were added and allowed to
incubate for 200s. Then, the current produced by the electrochemical
reduction of benzoquinone was measured.
2.3.6. Analysis of HFA in saliva
Saliva samples were obtained from volunteers and collected using a
Salivette® collection device (Sarstedt). Briefly, once rinsed the mouth
thoroughly with water, a cotton swab was inserted into the mouth
and chewed for 1min. Then, the swap saturated with saliva was in-
serted into the vial, sealed with the cap and centrifuged for 10min at
3000rpm. After this, 10-μL sample aliquots were diluted with 990μL of
0.01 PBS of pH 7.4. The determination was performed immediately by
applying the procedure described above to 5μL of diluted saliva, and
interpolation of the amperometric response into the calibration plot con-
structed with standard solutions.
3. Results and discussion
As described in Procedure 2.3.2, m-MWCNTs were prepared by
acidic oxidation of MWCNTs followed by incorporation of magnetic par-
ticles according with the method of Zhang et al. (2014) with slight mod-
ifications. Briefly, this procedure consisted of the treatment of carboxy-
lated MWCNTs with FeCl⁠3·6H⁠2O and FeCl⁠2·4H⁠2O in ammonia solution
at 80°C under nitrogen atmosphere. Thereafter (Fig. 1 inset), anti-HFA
and HRP were covalently immobilized onto the prepared m-MWCNTs
through EDC-NHSS chemistry (Akter et al., 2016). Fig. 1 also shows
schematically the different steps involved in the preparation of the
m-MWCNTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE im-
munosensor. As it was described in the Experimental section, the SPCE
surface was functionalized by grafting of p-ABA cation radical followed
by covalent immobilization of streptavidin. The biotinylated capture an-
tibody, anti-HFA-Biotin, was immobilized trough streptavidin-biotin in-
teraction and a sandwich assay configuration was implemented with
m-MWCNTs(-HRP)-anti-HFA.
The determination of HFA was accomplished by measuring the cur-
rent produced by the electrochemical reduction of benzoquinone at
−200 mV upon addition of H⁠2O⁠2 as HRP substrate.
Magnetic MWCNTs (m-MWCNTs) were characterized by scanning
electron microscopy (SEM), transmission electron microscopy (TEM),
X-Ray diffraction (XRD) and energy-dispersive X-Ray spectroscopy
(EDS). As it can be seen in Fig. 2a and b, as well as in the photograph
showing MWCNTs and m-MWCNTs upon applying an external magnet,
Fe⁠3O⁠4 particles were attached to the walls of MWCNTs. X-Ray diffrac-
tion recordings of m-MWCNTs and MWCNTs are shown in Fig. 2c. It
can be observed the peaks corresponding to the structure of MWCNTs
(red response) also appearing in that of m-MWCNTs (blue response), to-
gether with other peaks that can be attributed to the different types of
common iron oxides (Kim et al., 2010) (Gong et al., 2009). Peaks ap-
pearing at 2θ = 30.2°; 35.7°; 43.3° and 57.2° can be assigned to mag-
netite (Mn, Fe⁠3O⁠4) or maghemite (Mh, γ-Fe⁠2O⁠3). Other peaks appearing
at 2θ = 53.9° and 62.8° can be related to the presence of the non-mag-
netic (Hm, α-Fe⁠2O⁠3). Moreover, chemical analysis using EDS (Fig. 2d)
demonstrated the presence of Fe, O and C in the m-MWCNTs.
The room-temperature magnetization hysteresis loop of m-MWCNTs
was obtained using a vibrating sample magnetometer and compared
with those of HOOC-MWCNTs and pure Fe⁠3O⁠4 particles prepared under
the same reaction conditions. The results shown in Fig. S2 (Supplemen-
tary material) demonstrated the superparamagnetic behavior of m-MW-
CNTs, with a saturation magnetization of 9.89 emu/g, which, as ex-
pected, was significantly lower than that of Fe⁠3O⁠4 particles (62.12 emu/
g) owing to the presence of carbon nanotubes.
3.1. Optimization of the experimental variables
The different variables affecting the preparation of m-MWC-
NTs(-HRP)-anti-HFA conjugate, anti-HFA-Biotin-Strept-Phe-SPCE, and
the performance of the resulting m-MWC-
NTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE im-
munosensor were evaluated and optimized. The largest ratio between
the currents measured with the as prepared immunosensor in the pres-
ence (S), at a 250 pg/mL concentration level, or in the absence (N)
of the target compound was taken as the selection criterion for each
tested variable. The optimization studies involved evaluation of: a)
loadings of HRP and anti-HFA onto m-MWCNTs; b) loading of strep-
tavidin covalently linked to p-ABA-modified SPCE; c) anti-HFA-Biotin
loading onto Strept-Phe-SPCE; d) concentration of blocking agent. The
results of these tests are discussed in the
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Fig. 1. Schematic display of the different steps involved in the construction of the amperometric immunosensor for HFA involving p-ABA grafting onto SPCEs and covalent immobilization
of Strept followed by Biotin-anti-HFA conjugation and sandwich assay with m-MWCNTs(-HRP)-anti-HFA.
Supplementary material (Figs. S2-S4). Moreover, the experimental con-
ditions used for SPCE modification by grafting from the electrochemi-
cally generated p-ABA cation radical and covalent bond of streptavidin
were optimized previously (Ojeda et al., 2012). Similarly, the detection
potential of − 200 mV was also previously selected for the same cat-
alytic system (Eguílaz et al., 2010).
All the steps involved in the immunosensor preparation were moni-
tored by electrochemical impedance spectroscopy and cyclic voltamme-
try using 2 mM Fe(CN)⁠6⁠4−/3− as the redox probe in 0.1 M phosphate
buffer solution of pH 7.4. Fig. 3a shows as modification of the SPCE with
p-ABA gave rise to a large increase in the electron transfer resistance,
R⁠CT, varying from 376 to 1885 Ω as a consequence of the electrosta-
tic repulsion between the redox probe and the negatively charged car-
boxylate groups. After activation with EDC/NHSS and immobilization
of streptavidin, the R⁠CT value dramatically decreased (R⁠CT = 957 Ω),
while showed a further increase after conjugation with anti-HFA-Bi-
otin (R⁠CT = 1513 Ω) due to the partially insulating barrier on the elec-
trode surface produced by the presence of proteins. The blocking of
the remaining unreacted sites with biotin produced a larger R⁠CT value
of 1711 Ω in agreement with the expected decrease in the electrode
conductivity at a quasi-passivated surface. Surprisingly, further con-
jugation of HFA antigen provoked a decrease in the charge transfer
resistance, R⁠CT = 1497 Ω. A possible explanation of this behavior re-
lies with incorporation of biotin, which is dissociated at the work-
ing pH value, and provokes a high increase in R⁠CT due to charge re-
pulsion. The subsequent incorporation of the antigen led the charge
transfer resistance to values similar that measured before the block-
ing step. In addition, lower R⁠CT (1184 Ω) was observed for the m-MW-
CNTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE im-
munosensor probably as
a consequence of the high conductivity inherent to the modified carbon
nanotubes.
Similar changes and conclusions were apparent from CV especially
in the early stages of immunosensor preparation. The voltammogram
corresponding to the bare SPCE (curve 1) shows the characteristic ox-
idation and reduction peaks of the redox pair at potential values of
+ 0.27 and − 0.06 V, respectively, while the anodic and cathodic cur-
rents exhibited approximately the same magnitude (130 μA). Modifica-
tion of SPCE by grafting with p-ABA (curve 2) caused a decrease in the
peak currents and a larger separation of peak potentials which is most
likely due to the electrostatic repulsion between the redox probe and the
dissociated carboxyl groups on the electrode surface. When streptavidin
is linked (curve 3), the corresponding voltammogram shows a behav-
ior more similar that of the unmodified electrode, probably due to the
lower effect of charge repulsion. Successive incorporation of the other
immunoreagents provoked slight variations in the CVs towards a less re-
versible behavior, as a consequence of the presence of insulating layers
of increasing thickness on the electrode surface.
3.2. Analytical characteristics for HFA determination
Under the optimized working conditions, a calibration plot for HFA
(Fig. 4) was constructed over the 10–5000 pg/mL concentration range.
A linear range between 20 and 2000 pg/mL was found (r⁠2 = 0.995)
which fitted to the equation: i, μA = 2.17 ± 0.07 log [HFA, pg/mL]
− 2.22 ± 0.4. A mandatory comparison is the calibration plot con-
structed using MWCNTs(-HRP)-anti-HFA as the carrier tag, i.e., without
magnetic particles incorporated to the nanotubes. In this latter case, a
calibration graph with a lower slope value (1.21 ± 0.05 μA per decade of
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Fig. 2. Scanning electron microscopy (SEM) and photograph showing MWCNTs and m-MWCNTs with an external magnet (a); transmission electron microscopy (TEM) (b); X-Ray diffrac-
tion (XRD) (c) and energy dispersion spectrum (EDS) (d) of HOOC-MWCNTs (a, b, d-left; c-red), and m-MWCNTs (a, b, d-right; c-blue). (For interpretation of the references to color in this
figure legend, the reader is referred to the web version of this article.).
concentration) was obtained over the same dynamic range (r⁠2 = 0.997).
The higher sensitivity achieved with the magnetic nanoparticles high-
lights their favorable contribution to enhance conductivity and abil-
ity of carbon nanotubes for biomolecules adsorption. According
with Zhang et al. (2014), m-MWCNTs used as labels of anti-HFA sec-
ondary antibodies offer a large specific surface area and promote elec-
tron transfer between the solution and the electrode. The improved an-
alytical performance can also be partially attributable to the magnetic
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Fig. 3. Nyquist plots (a) and cyclic voltammograms (b) recorded in a 2 mM Fe(CN)⁠6
⁠3−/4− 0.1 M phosphate buffer solution of pH 7.4 for bare SPCE (1); p-ABA-SPCE (2);
Strept-Phe-SPCE (3); anti-HFA-Biotin-Strept-Phe-SPCE (4); blocking with Biotin (5);
HFA-anti-HFA-Biotin-Strept-Phe-SPCE (6); m-MWCNTs(-HRP)-anti-HFA-HFA-anti-HFA-Bi-
otin-Strept-Phe-SPCE (7); 250 pg/mL HFA; range of frequencies, 10⁠5–0.040 Hz; open cir-
cuit (a); 50 mV/s (b).
Fig. 4. Calibration plot for HFA constructed with the mMWC-
NTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE immunosensor.
particles weak pseudo-peroxidase activity. Nevertheless, the enzymatic
catalysis by HRP of the hydrogen peroxide reaction is much more
important, as it can be deduced from the much smaller slope value,
m = 0.102 ± 0.02 μA per decade of concentration, of the calibration
graph in the same range of HFA concentrations constructed with the
immunosensor using m-MWCNTs-anti-HFA label without HRP enzyme.
This biosensor showed also a poorer linearity (r⁠2 = 0.95). To high-
light the relevant effect for signal amplification provided by the use
of m-MWCNTs(-HRP)-anti-HFA label, the results obtained with the as
prepared m-MWCNTs(-HRP)-anti-HFA-HFA immunosensor were com-
pared with those achieved with a HRP-IgG-anti-HFA-HFA-anti-HFA-Bi-
otin-Strept-Phe-SPCE immunosensor. Fig. S5 in Supplementary material
shows as the current measured for 250 pg/mL HFA was approximately
three times larger using m-MWCNTs(-HRP)-anti-HFA conjugate as the
carrier tag. Moreover, despite the higher current achieved for HFA de-
tection, the unspecific signals represented only less than 13 per cent of
such magnitude, thus providing a high S/N ratio.
The linear range of the calibration plot (20–2000 pg/mL) covers
much lower HFA concentrations and in a wider interval than those
claimed for the ELISA kit (https://www.rndsystems.com/products/
human-fetuin-a-quantikine-elisa-kit_dfta00), 7.8–500 ng/mL HFA, as
well as the comparison is made against the electrochemical immunosen-
sor reported by Silva et al. (2016), 0.5–25 μg/mL. The limit of detec-
tion achieved with our immunosensor design was calculated according
with the 3 s⁠b/m criterion, where s⁠b was estimated as the standard devi-
ation, expressed in concentration units, for 10 blank current measure-
ments (0 pg/mL HFA). The obtained LOD value, 16 pg/mL, is notably
better (more than 10⁠3 times lower) than that reported in (Silva et al.,
2016), 0.017 μg/mL, and the minimum detectable dose (MDD) of the
ELISA kit, 0.62 ng/mL.
The reproducibility of the measurements performed with the devel-
oped immunosensor was evaluated. Amperometric measurements for
0 and 250 pg/mL HFA were made with five different immunosensors
prepared simultaneously for each HFA concentration. The calculated
RSD values were 6.7% and 7.4%, respectively. Moreover, measurements
were also carried out with five immunosensors prepared in five dif-
ferent days. In this case, the RSD values were 7.2% and 7.5% for the
same concentration levels, respectively. On the other hand, the storage
stability of anti-HFA-Biotin-Strept-Phe-SPCEs was evaluated by prepar-
ing the same day various immunosensors which were used for measur-
ing the amperometric responses of 250 pg/mL HFA in different days,
once the blocking reagent and the m-MWCNTs(-HRP)-anti-HFA conju-
gate were added. Between measurements, the bioelectrodes were stored
at − 20 °C in dry ambient. The results obtained (Fig. S6a) revealed
that the initial immunosensor response was maintained within the lim-
its of control set by ± 3 times the standard deviation of the measure-
ments (n = 3) carried out on the first day, during 40 days after the im-
munosensor preparation thus showing an excellent storage stability.
In addition, the stability of the m-MWCNTs(-HRP)-anti-HFA conju-
gates was also checked by preparing an amount of them and keeping in
the refrigerator at 4 °C. A new immunosensor was prepared each work-
ing day with a different conjugate and used to measure the current cor-
responding to 250 pg/mL HFA. The results shown in Fig. S6b confirmed
a storage stability of the conjugates for at least 30 days after their prepa-
ration.
3.3. Selectivity
Various proteins (bovine serum albumin (BSA), interleukin 1 beta
(IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), human immunoglob-
ulin G (IgG), tumor necrosis factor alpha (TNF–α), and transforming
growth factor beta 1 (TGF–β1)), as well as other compounds poten-
tially present in samples containing HFA, such as creatinine (CR), ascor-
bic acid (AA), uric acid (UA), cortisol (CL), and estradiol (E2) were
tested as potential interfering substances for the determination of HFA
with the developed immunosensor. The evaluation of the selectivity
was accomplished by comparing the immunosensor responses for 0 and
250 pg/mL HFA in the absence and in the presence of each tested com-
pound at a concentration corresponding approximately to the normal
level in the undiluted saliva samples, except BSA, which was tested at
a higher concentration. Fig. 5 shows that not significantly different cur-
rents were measured in all cases with the current mean values within
the ± 2 × standard deviation range of the current measured in the ab-
sence of interferent.
Fig. 5. Effect of the presence of 5 mg/mL bovine serum albumin (BSA), 50 pg/mL in-
terleukin 1 beta (IL–1β), 50 pg/mL interleukin 6 (IL–6), 250 pg/mL interleukin 8 (IL–8),
16 μg/mL human immunoglobulin G (IgG), 200 pg/mL tumor necrosis factor alfa (TNF–α),
500 pg/mL transforming growth factor beta 1 (TGF–β1), 10 pg/mL creatinine (CR),
370 µg/mL ascorbic acid (AA), 50 µg/mL uric acid (UA), 12 ng/mL cortisol (CL), and
200 pg/mL estradiol (E2) on the amperometric responses obtained for 0 (■) or 250 (■)
pg/mL HFA at the mMWCNTs(-HRP)-anti-HFA-HFA-anti-HFA-Biotin-Strept-Phe-SPCE im-
munosensor.
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3.4. Determination of HFA in saliva
The usefulness of the immunosensor in the analysis of real samples
was tested by analyzing saliva from two smoker and non-smoker-volun-
teers. This type of sample was chosen because, as indicated in the Intro-
duction section, HFA plays an important role in the detection of dental
inflammatory processes (Doğan al, 2016). In addition, saliva is increas-
ingly recognized as an attractive fluid for diagnostics since it allows a
non-invasive cost-efficient sample collection method among other ad-
vantages (Campuzano et al., 2017). With the aim of minimizing the
possible matrix effects and to fit the HFA concentration in the samples
within the obtained range of linearity, various saliva dilution factors us-
ing 0.01 M PBS of pH 7.4 were assayed. As it is shown below, these re-
quirements were achieved by applying a 100-fold dilution to the sam-
ple.
Under these conditions, the possible existence of matrix effects was
tested by comparing the slope value of the calibration plots constructed
by successive addition of HFA standard aliquots to the diluted samples,
with the slope of the calibration graph prepared with buffered HFA
standard solutions (Fig. 4). Slope values of 2.16 ± 0.03 and 2.17 ± 0.03
μA per decade of concentration were found in non-smoker and smoker
saliva, respectively, which were very similar to that of the calibration
graph constructed with HFA standards, 2.17 ± 0.07 μA per decade of
concentration. The application of the Student t-test provided t⁠exp values
much lower than the tabulated one, t⁠tab = 2.262 for α = 0.05 and n = 9.
Therefore, the determination of HFA in saliva could be performed di-
rectly by interpolation of the amperometric current measured with the
immunosensor for an aliquot of the 100-fold diluted sample into the cal-
ibration plot constructed with standard solutions. Fig. S7 (Supplemen-
tary Material) displays the calibration plot obtained with the saliva sam-
ples overlapped with that constructed from standard HFA solutions in
PB buffer showing the coincidence between them.
The concentrations found in the analysis of the saliva samples were
44.6 ± 0.5 and 43.0 ± 0.2 ng/mL for the smoker and non-smoker indi-
viduals (n = 5) showing, as expected, that no important differences
are apparent in the absence of inflammatory disease. These results
were compared with those obtained using the commercial ELISA kit,
44.8 ± 0.8 ng/mL and 42.9 ± 0.6 ng/mL (n = 4), respectively. As it is
obvious, an excellent agreement between the results obtained by both
methods was apparent, what is also in agreement with that reported
in the literature for saliva of healthy individuals, 41 ng/mL (Doğan al,
2016). All these results demonstrated the usefulness of the developed
immunosensor for the analysis of HFA at low concentration levels in
saliva with minimal sample treatment.
4. Conclusions
This paper reports the first amperometric immunosensor for the
determination of the biomarker HFA. The designed strategy involved
SPCEs grafted with p-aminobezoic acid for covalent binding of strep-
tavidin, and a sandwich configuration with biotinylated capture anti-
body and magnetic MWCNTs conjugated with HRP and anti-HFA anti-
bodies as the detection label. The use of this signal amplification ap-
proach provides important analytical advantages in terms of wider lin-
ear dynamic concentration range and sensitivity with respect to com-
mercial ELISA kits as well as to the only electrochemical immunosensor
(chronoimpedimetric) reported so far for HFA. Importantly, the devel-
oped immunosensor can be used to determine HFA in saliva with min-
imal sample treatment. Other relevant advantages of the developed im-
munosensor are the great reproducibility of the measurements, both
with immunosensors prepared on the same day and on different days,
and the excellent storage stability and selectivity. This immunosens-
ing strategy can be easily extended to the electrochemical determina-
tion of other biomarkers since the disposable electrode surface modifi-
cation protocol and the use of magnetic multiwalled carbon nanotubes
as nanocarrier tags can be viewed as general working approaches to de-
sign other electrochemical immunoplatforms.
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